Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Paricalcitol (Zemplar) Clear all
Withdrawn Not applicable Interventional

The Effects of Active VItamin D on Left Atrial Volume Index

NCT01630408
View directory record Official record
Conditions
Heart Failure
Interventions
Paricalcitol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Sep 18, 2026, 5:47 PM EDT
Active, not recruiting Early Phase 1 Interventional

PHL Treatment in Pancreatic Cancer

NCT05365893
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Paricalcitol, Hydroxychloroquine, Losartan, Neoadjuvant therapy and surgery only (Control)
Combination Product · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 18, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease

NCT01012414
View directory record Official record
Conditions
Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
Interventions
paricalcitol, placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 18, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions
Paricalcitol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

NCT00421733
View directory record Official record
Conditions
Diabetic Nephropathy, Chronic Kidney Disease
Interventions
Zemplar (paricalcitol) capsules, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
27
States / cities
Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)

NCT00048516
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
paricalcitol capsule
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
16
States / cities
Los Angeles, California • Riverside, California • Simi Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Sep 18, 2026, 5:47 PM EDT
Terminated Early Phase 1 Interventional Results available

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

NCT03519308
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Nivolumab, Nab-Paclitaxel, Gemcitabine, Paricalcitol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 18, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

NCT00258258
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
paricalcitol, zoledronic acid
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 4 Interventional

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

NCT00073710
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

NCT00417612
View directory record Official record
Conditions
Hypophosphatemia, Familial, Hyperparathyroidism
Interventions
Paricalcitol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
9 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

NCT00048451
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
paricalcitol
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
18
States / cities
Tucson, Arizona • Pasadena, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Sep 18, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

NCT00616902
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
Interventions
paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Phoenix, Arizona • Tempe, Arizona • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 4 Interventional

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

NCT00053547
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Renal Disease
Interventions
paricalcitol injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

NCT00977080
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
Interventions
Paricalcitol, Cinacalcet
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

NCT00064376
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
paricalcitol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
25 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Oral Paricalcitol in Kidney Transplant Recipients

NCT00587158
View directory record Official record
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Immune Effects of Vitamin D in Hemodialysis Patients

NCT00686751
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
Interventions
paricalcitol
Drug
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2009 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Results available

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

NCT00823303
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Paricalcitol, Calcitriol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

NCT03415854
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma
Interventions
Paricalcitol (Zemplar)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

NCT00463021
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
8
States / cities
Downey, California • Paramount, California • Hudson, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 18, 2026, 5:47 PM EDT
Active, not recruiting Early Phase 1 Interventional

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

NCT05664880
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Paricalcitol, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

NCT00646035
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
paricalcitol capsules
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
22
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Sep 18, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery

NCT01138475
View directory record Official record
Conditions
Gastric Bypass, Parathyroid Hormone
Interventions
Paricalcitol, Cholecalciferol, Placebo
Drug
Lead sponsor
Kerstyn C. Zalesin, M.D.
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 18, 2026, 5:47 PM EDT
Terminated Phase 4 Interventional Results available

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

NCT01725113
View directory record Official record
Conditions
Kidney Failure, Secondary Hyperparathyroidism, Hyperphosphatemia, Hypercalcemia
Interventions
Calcitriol, Paricalcitol
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 18, 2026, 5:47 PM EDT